|

Ferinject Clinical Trials

2 actively recruiting trials

Also known as: Ferric carboxymaltose

Pipeline

Phase 4: 2

Top Sponsors

  • Wroclaw Medical University1
  • Tomsk National Research Medical Center of the Russian Academy of Sciences1

Indications

  • Heart Disease2
  • Iron Deficiency, Latent1
  • Myocardial Infarction, Acute1
  • Chronic Heart Failure1

Other2 trials

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
Phase 4
The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.